These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9073527)

  • 21. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.
    Carreño V; Zeuzem S; Hopf U; Marcellin P; Cooksley WG; Fevery J; Diago M; Reddy R; Peters M; Rittweger K; Rakhit A; Pardo M
    J Hepatol; 2000 Feb; 32(2):317-24. PubMed ID: 10707873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical safety, pharmacokinetics, and pharmacodynamics of recombinant human interleukin-21 in cynomolgus macaques (Macaca fascicularis).
    Waggie KS; Holdren MS; Byrnes-Blake K; Pedersen S; Ponce R; Hughes S; Miller DM
    Int J Toxicol; 2012; 31(4):303-16. PubMed ID: 22723515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys.
    Yu KM; Lau JY; Fok M; Yeung YK; Fok SP; Zhang S; Ye P; Zhang K; Li X; Li J; Xu Q; Wong WT; Choo QL
    Toxicol Appl Pharmacol; 2018 Mar; 342():39-49. PubMed ID: 29407773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects.
    Angel JB; Jacobson MA; Skolnik PR; Giordano M; Shapiro L; LeBeaut A; Greaves W; Fuchs AC
    AIDS; 2000 Nov; 14(16):2503-8. PubMed ID: 11101061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
    Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical safety of recombinant human thrombin.
    Heffernan JK; Ponce RA; Zuckerman LA; Volpone JP; Visich J; Giste EE; Jenkins N; Boster D; Pederson S; Knitter G; Palmer T; Wills M; Early RJ; Rogge MC
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):48-58. PubMed ID: 16971028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
    Schreiber S; Fedorak RN; Nielsen OH; Wild G; Williams CN; Nikolaus S; Jacyna M; Lashner BA; Gangl A; Rutgeerts P; Isaacs K; van Deventer SJ; Koningsberger JC; Cohard M; LeBeaut A; Hanauer SB
    Gastroenterology; 2000 Dec; 119(6):1461-72. PubMed ID: 11113067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic, pharmacodynamic, and pharmacotoxic profiles of recombinant-methionyl human interleukin-2[alanine-125] (r-metHuIL-2[ala-125]) following intravenous and subcutaneous administration in rats.
    LeBel CP; Langlois L; Bell DP; Young JD; Kenney WC; Payne BJ; Sendelbach LE; Wong LC
    Hum Exp Toxicol; 1995 Nov; 14(11):909-15. PubMed ID: 8588953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
    Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
    Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
    Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of antitumor activity and intolerance of interleukin-4 in patients with advanced HIV disease and Kaposi's sarcoma.
    Miles SA; Testa M; Huang J; Wade M; Carden J; Scadden DT
    J Interferon Cytokine Res; 2002 Nov; 22(11):1143-8. PubMed ID: 12513914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I]recombinant human interleukin-2 in cynomolgus monkeys.
    Nadeau RW; Satoh H; Scheide S; Crowl R; Conroy R; Garland WA; Liberato DJ
    Drug Metab Dispos; 1995 Sep; 23(9):904-9. PubMed ID: 8565779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.
    Moreland L; Gugliotti R; King K; Chase W; Weisman M; Greco T; Fife R; Korn J; Simms R; Tesser J; Hillson J; Caldwell J; Schnitzer T; Lyons D; Schwertschlag U
    Arthritis Res; 2001; 3(4):247-52. PubMed ID: 11438043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From laboratory to Phase I/II cancer trials with recombinant biotherapeutics.
    Tolner B; Smith L; Hillyer T; Bhatia J; Beckett P; Robson L; Sharma SK; Griffin N; Vervecken W; Contreras R; Pedley RB; Begent RH; Chester KA
    Eur J Cancer; 2007 Nov; 43(17):2515-22. PubMed ID: 17933516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals.
    Dumont JA; Loveday KS; Light DR; Pierce GF; Jiang H
    Thromb Res; 2015 Dec; 136(6):1266-72. PubMed ID: 26514955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Technology evaluation: SB-485232, GlaxoSmithKline.
    Golab J; Stoklosa T
    Curr Opin Mol Ther; 2005 Feb; 7(1):85-93. PubMed ID: 15732534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy.
    Zamkoff KW; Newman NB; Rudolph AR; Young J; Poiesz BJ
    J Biol Response Mod; 1989 Oct; 8(5):539-52. PubMed ID: 2795095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.